American Society of Hirudotherapy

Congenital dysfibrinogenemia

Review published in Current opinion in hematology (1997)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentMartinez · Current opinion in hematology, 1997

Abstract

Fibrinogen abnormalities can be classified as congenital or acquired. Each class manifests quantitative or qualitative alterations; the latter are known as dysfibrinogenemias. In dysfibrinogenemias, structural defects cause alterations in the conversion of fibrinogen to fibrin. Approximately 300 abnormal fibrinogens have been reported, and about 83 structural defects have been identified. The most common structural defect involve the fibrinopeptides and their cleavage sites, and the second most common involves the gamma-chain polymerization region. Approximately half of the mutants are clinically silent, whereas hemorrhage and thrombosis occur in almost equal numbers of cases. Study of the abnormal fibrinogens has provided insight into fibrinogen structure and fibrin formation and dissolution. Some of the structural abnormalities exhibit defective assembly and activation of components of the fibrinolytic system on the abnormal fibrin, resulting in impaired dissolution of fibrin, clinically associated with thrombosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAfibrinogenemiaFibrinogenFibrinogens, AbnormalHumansModels, MolecularThrombosisWound Healing

Summary

This review describes congenital dysfibrinogenemia, in which structural defects—most often at fibrinopeptide cleavage sites or the gamma-chain polymerization region—alter fibrin formation; about half of roughly 300 reported abnormal fibrinogens are clinically silent, while hemorrhage and thrombosis occur in near-equal numbers.

Context

This review of congenital dysfibrinogenemia describes how structural defects in fibrinogen, with roughly 300 abnormal fibrinogens and about 83 identified structural defects reported, alter the conversion of fibrinogen to fibrin; about half are clinically silent while hemorrhage and thrombosis occur in nearly equal numbers, and some abnormal fibrins resist fibrinolysis, producing thrombosis. It provides background on fibrin formation and dissolution, the very system that leech-derived molecules act on, since the secretome includes agents studied for their effects on fibrin clot formation and breakdown. This is a narrative review of an inherited coagulation disorder from the 1990s; it does not address leeches, hirudotherapy, or any treatment outcome, and is included only to explain fibrinogen biology.

Citation

Reference (Vancouver style)

Martinez J. Congenital dysfibrinogenemia. Curr Opin Hematol. 1997;4(5):357-365. doi:10.1097/00062752-199704050-00010. PMID: 9288470

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.